Theriva Biologics, Inc. (TOVX) 10-Year Financial Performance & Capital Metrics

TOVX • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutTheriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.Show more

Revenue $0
EBITDA -$26M -23.1%
Net Income -$26M -39.8%
EPS (Diluted) -19.03 +33.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -87.31% -124.3%
ROIC -142.68% -47.1%
Debt/Equity 0.08 +51.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM83.27%

ROCE

10Y Avg-168.65%

5Y Avg-59.2%

3Y Avg-46.58%

Latest-69.11%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	72K	157K	245K	272K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-72K	-157K	-245K	-272K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1.18%	-0.56%	-0.11%	1%	-	-	-	-	-
Operating Expenses+	40.98M	39.25M	26.25M	17.57M	15.66M	10.16M	14.27M	21.58M	21.43M	26.35M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.07M	10.14M	7.47M	5.73M	4.58M	5.03M	6.47M	7.57M	7.78M	7.4M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	32.91M	29.11M	18.78M	11.84M	11.08M	5.13M	7.8M	11.72M	14.31M	12.03M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	2.29M	-660K	6.92M
Operating Income+	-40.98M	-39.25M	-26.25M	-17.57M	-15.66M	-10.16M	-14.27M	-21.58M	-21.43M	-26.35M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1%	0.04%	0.33%	0.33%	0.11%	0.35%	-0.4%	-0.51%	0.01%	-0.23%
EBITDA+	-40.91M	-39.09M	-26.01M	-17.3M	-15.42M	-9.96M	-14.19M	-21.5M	-21.3M	-26.21M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1%	0.04%	0.33%	0.33%	0.11%	0.35%	-0.42%	-0.52%	0.01%	-0.23%
D&A (Non-Cash Add-back)	72K	157K	245K	272K	240K	201K	87K	85K	135K	137K
EBIT	-40.98M	-39.25M	-26.25M	-17.57M	-15.66M	-10.16M	-14.27M	-19.29M	-22.09M	-19.43M
Net Interest Income+	0	0	0	0	283K	44K	6K	512K	1.44M	697K
Interest Income	6K	37K	21K	67K	283K	44K	6K	512K	1.44M	697K
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-3.81M	11.45M	10.76M	4.15M	283K	44K	6K	471K	1.44M	693K
Pretax Income+	-44.78M	-27.8M	-15.49M	-13.42M	-15.38M	-10.12M	-14.27M	-21.11M	-19.99M	-25.65M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	-1.43M	-1.64M	0
Effective Tax Rate %	0.98%	0.98%	0.98%	1%	0.99%	0.99%	1%	0.93%	0.92%	1%
Net Income+	-43.74M	-27.25M	-15.17M	-13.37M	-15.3M	-10.04M	-14.27M	-19.68M	-18.35M	-25.65M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.21%	0.38%	0.44%	0.12%	-0.14%	0.34%	-0.42%	-0.38%	0.07%	-0.4%
Net Income (Continuing)	-44.78M	-27.8M	-15.49M	-13.42M	-15.38M	-10.12M	-14.27M	-19.68M	-18.35M	-25.65M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-1.05M	-1.6M	-1.91M	-2.91M	-2.88M	-2.77M	0	0	0	0
EPS (Diluted)+	-189.68	-101.17	-42.70	-21.45	-9.14	-6.60	-1.90	-32.66	-28.48	-19.03
EPS Growth %	-0.7%	0.47%	0.58%	0.5%	0.57%	0.28%	0.71%	-16.19%	0.13%	0.33%
EPS (Basic)	-189.68	-101.17	-42.70	-21.45	-9.14	-6.60	-1.90	-32.66	-28.49	-19.03
Diluted Shares Outstanding	230.58K	269.4K	355.33K	623.24K	1.64M	1.9M	12.19M	613.09K	644.28K	1.35M
Basic Shares Outstanding	230.58K	269.4K	355.33K	623.24K	1.64M	1.9M	12.19M	613.09K	644K	1.35M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	30.34M	21.57M	17.94M	29.51M	16.43M	7.93M	68.86M	45.52M	27.4M	16.28M
Cash & Short-Term Investments	20.82M	19.05M	17.12M	28.92M	15.04M	6.23M	67.33M	41.79M	23.18M	11.61M
Cash Only	20.82M	19.05M	17.12M	28.92M	15.04M	6.23M	67.33M	41.79M	23.18M	11.61M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	185K	46K	0	3K	469K	0	231K	1.94M	3.32M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	8.97M	1.68M	0	0	0	0	458K	0	0	0
Total Non-Current Assets+	508K	928K	895K	630K	809K	476K	1.51M	26.34M	27.82M	19.07M
Property, Plant & Equipment	494K	905K	872K	607K	786K	453K	1.48M	1.54M	2.18M	1.54M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	5.53M	5.7M	0
Intangible Assets	0	0	0	0	0	0	0	19.15M	19.75M	17.36M
Long-Term Investments	0	0	0	0	0	0	0	99K	102K	0
Other Non-Current Assets	14K	23K	23K	23K	23K	23K	23K	-3.15M	78K	171K
Total Assets+	30.84M	22.5M	18.84M	30.14M	17.23M	8.41M	70.36M	71.86M	55.22M	35.35M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.61%	-0.27%	-0.16%	0.6%	-0.43%	-0.51%	7.37%	0.02%	-0.23%	-0.36%
Total Current Liabilities+	15.57M	19.76M	9.79M	3.38M	5.28M	2.97M	3.55M	7.06M	6.74M	7.58M
Accounts Payable	4.41M	1.99M	2.02M	1.03M	2.31M	886K	524K	915K	770K	859K
Days Payables Outstanding	22.37K	4.63K	3.01K	1.39K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	57K	63K	61K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	10.59M	14.82M	4.17M	99K	0	868K	0	4.47M	906K	1.8M
Current Ratio	1.95x	1.09x	1.83x	8.72x	3.11x	2.67x	19.37x	6.45x	4.07x	2.15x
Quick Ratio	1.95x	1.09x	1.83x	8.72x	3.11x	2.67x	19.37x	6.45x	4.07x	2.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	267K	492K	12.46M	302K	473K	186K	1.4M	10.24M	8.78M	8.7M
Long-Term Debt	0	0	0	0	0	0	0	221K	162K	92K
Capital Lease Obligations	0	0	0	0	473K	186K	1.4M	1.19M	1.44M	873K
Deferred Tax Liabilities	0	0	0	0	0	0	0	1.62M	0	762K
Other Non-Current Liabilities	267K	492K	402K	302K	0	0	0	7.21M	7.18M	6.97M
Total Liabilities	15.84M	20.25M	22.25M	3.69M	5.75M	3.15M	4.96M	17.3M	15.52M	16.29M
Total Debt+	0	0	0	0	722K	473K	1.53M	1.68M	2.15M	1.56M
Net Debt	-20.82M	-19.05M	-17.12M	-28.92M	-14.32M	-5.75M	-65.8M	-40.1M	-21.02M	-10.04M
Debt / Equity	-	-	-	-	0.06x	0.09x	0.02x	0.03x	0.05x	0.08x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	15M	2.25M	-3.41M	26.45M	11.49M	5.26M	65.41M	54.56M	39.7M	19.07M
Equity Growth %	0.57%	-0.85%	-2.52%	8.76%	-0.57%	-0.54%	11.44%	-0.17%	-0.27%	-0.52%
Book Value per Share	65.07	8.35	-9.60	42.45	6.99	2.77	5.37	89.00	61.61	14.14
Total Shareholders' Equity	16.05M	3.85M	-1.5M	29.36M	14.37M	8.03M	65.41M	54.56M	39.7M	19.07M
Common Stock	91K	117K	129K	15K	17K	29K	13K	16K	18K	3K
Retained Earnings	-144.78M	-172.03M	-194.17M	-219.46M	-235.54M	-248.09M	-271.28M	-290.97M	-309.32M	-334.97M
Treasury Stock	0	0	0	0	0	0	0	-288K	-288K	-288K
Accumulated OCI	0	0	-12.05M	0	0	0	0	-679K	32K	-1.18M
Minority Interest	-1.05M	-1.6M	-1.91M	-2.91M	-2.88M	-2.77M	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38.89M	-27.9M	-20.2M	-17.28M	-13.87M	-12.17M	-12.89M	-19.08M	-19M	-16.94M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.42%	0.28%	0.28%	0.14%	0.2%	0.12%	-0.06%	-0.48%	0%	0.11%
Net Income	-44.78M	-27.8M	-15.49M	-13.42M	-15.38M	-10.12M	-14.27M	-19.68M	-18.35M	-25.65M
Depreciation & Amortization	72K	157K	245K	272K	240K	201K	87K	85K	135K	137K
Stock-Based Compensation	3.2M	4.01M	3.41M	2.07M	340K	350K	416K	475K	552K	671K
Deferred Taxes	0	0	0	-4.08M	0	0	0	-1.43M	-1.64M	-888K
Other Non-Cash Items	8.16M	-11.41M	-10.74M	71K	72K	178K	166K	2.27M	-2M	8.07M
Working Capital Changes	-5.54M	7.15M	2.37M	-2.19M	855K	-2.78M	709K	-806K	2.31M	726K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	3.42M	-2.42M	27K	-987K	1.28M	-1.43M	-363K	-385K	-157K	123K
Cash from Investing+	-501K	-569K	-212K	-7K	0	-9K	-14K	-4.4M	-202K	-1K
Capital Expenditures	-501K	-569K	-212K	-7K	0	-9K	-14K	-116K	-202K	-1K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	-4.28K	0	0
Cash from Financing+	42.68M	26.71M	18.48M	29.09M	0	3.36M	74M	-1.93M	625K	5.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-3.32M	198K	166K	0	0	0	8.04M	-3M	-1.52M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-39.39M	-28.47M	-20.42M	-17.29M	-13.87M	-12.18M	-12.9M	-19.2M	-19.2M	-16.94M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.44%	0.28%	0.28%	0.15%	0.2%	0.12%	-0.06%	-0.49%	0%	0.12%
FCF per Share	-170.83	-105.68	-57.46	-27.74	-8.44	-6.41	-1.06	-31.31	-29.80	-12.56
FCF Conversion (FCF/Net Income)	0.89x	1.02x	1.33x	1.29x	0.91x	1.21x	0.90x	0.97x	1.04x	0.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-356.18%	-315.96%	-	-116.01%	-80.67%	-119.95%	-40.38%	-32.82%	-38.93%	-87.31%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-230.09%	-97.02%	-142.68%
Debt / Equity	-	-	-	-	0.06x	0.09x	0.02x	0.03x	0.05x	0.08x
FCF Conversion	0.89x	1.02x	1.33x	1.29x	0.91x	1.21x	0.90x	0.97x	1.04x	0.66x

Frequently Asked Questions

Growth & Financials

Theriva Biologics, Inc. (TOVX) grew revenue by 0.0% over the past year. Growth has been modest.

Theriva Biologics, Inc. (TOVX) reported a net loss of $26.2M for fiscal year 2024.

Dividend & Returns

Theriva Biologics, Inc. (TOVX) has a return on equity (ROE) of -87.3%. Negative ROE indicates the company is unprofitable.

Theriva Biologics, Inc. (TOVX) had negative free cash flow of $18.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Theriva Biologics, Inc. (TOVX) 10-Year Financial Performance & Capital Metrics

TOVX • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $0
EBITDA -$26M -23.1%
Net Income -$26M -39.8%
EPS (Diluted) -19.03 +33.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -87.31% -124.3%
ROIC -142.68% -47.1%
Debt/Equity 0.08 +51.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM83.27%

ROCE

10Y Avg-168.65%

5Y Avg-59.2%

3Y Avg-46.58%

Latest-69.11%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	72K	157K	245K	272K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-72K	-157K	-245K	-272K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1.18%	-0.56%	-0.11%	1%	-	-	-	-	-
Operating Expenses+	40.98M	39.25M	26.25M	17.57M	15.66M	10.16M	14.27M	21.58M	21.43M	26.35M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.07M	10.14M	7.47M	5.73M	4.58M	5.03M	6.47M	7.57M	7.78M	7.4M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	32.91M	29.11M	18.78M	11.84M	11.08M	5.13M	7.8M	11.72M	14.31M	12.03M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	2.29M	-660K	6.92M
Operating Income+	-40.98M	-39.25M	-26.25M	-17.57M	-15.66M	-10.16M	-14.27M	-21.58M	-21.43M	-26.35M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1%	0.04%	0.33%	0.33%	0.11%	0.35%	-0.4%	-0.51%	0.01%	-0.23%
EBITDA+	-40.91M	-39.09M	-26.01M	-17.3M	-15.42M	-9.96M	-14.19M	-21.5M	-21.3M	-26.21M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1%	0.04%	0.33%	0.33%	0.11%	0.35%	-0.42%	-0.52%	0.01%	-0.23%
D&A (Non-Cash Add-back)	72K	157K	245K	272K	240K	201K	87K	85K	135K	137K
EBIT	-40.98M	-39.25M	-26.25M	-17.57M	-15.66M	-10.16M	-14.27M	-19.29M	-22.09M	-19.43M
Net Interest Income+	0	0	0	0	283K	44K	6K	512K	1.44M	697K
Interest Income	6K	37K	21K	67K	283K	44K	6K	512K	1.44M	697K
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-3.81M	11.45M	10.76M	4.15M	283K	44K	6K	471K	1.44M	693K
Pretax Income+	-44.78M	-27.8M	-15.49M	-13.42M	-15.38M	-10.12M	-14.27M	-21.11M	-19.99M	-25.65M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	-1.43M	-1.64M	0
Effective Tax Rate %	0.98%	0.98%	0.98%	1%	0.99%	0.99%	1%	0.93%	0.92%	1%
Net Income+	-43.74M	-27.25M	-15.17M	-13.37M	-15.3M	-10.04M	-14.27M	-19.68M	-18.35M	-25.65M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.21%	0.38%	0.44%	0.12%	-0.14%	0.34%	-0.42%	-0.38%	0.07%	-0.4%
Net Income (Continuing)	-44.78M	-27.8M	-15.49M	-13.42M	-15.38M	-10.12M	-14.27M	-19.68M	-18.35M	-25.65M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-1.05M	-1.6M	-1.91M	-2.91M	-2.88M	-2.77M	0	0	0	0
EPS (Diluted)+	-189.68	-101.17	-42.70	-21.45	-9.14	-6.60	-1.90	-32.66	-28.48	-19.03
EPS Growth %	-0.7%	0.47%	0.58%	0.5%	0.57%	0.28%	0.71%	-16.19%	0.13%	0.33%
EPS (Basic)	-189.68	-101.17	-42.70	-21.45	-9.14	-6.60	-1.90	-32.66	-28.49	-19.03
Diluted Shares Outstanding	230.58K	269.4K	355.33K	623.24K	1.64M	1.9M	12.19M	613.09K	644.28K	1.35M
Basic Shares Outstanding	230.58K	269.4K	355.33K	623.24K	1.64M	1.9M	12.19M	613.09K	644K	1.35M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	30.34M	21.57M	17.94M	29.51M	16.43M	7.93M	68.86M	45.52M	27.4M	16.28M
Cash & Short-Term Investments	20.82M	19.05M	17.12M	28.92M	15.04M	6.23M	67.33M	41.79M	23.18M	11.61M
Cash Only	20.82M	19.05M	17.12M	28.92M	15.04M	6.23M	67.33M	41.79M	23.18M	11.61M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	185K	46K	0	3K	469K	0	231K	1.94M	3.32M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	8.97M	1.68M	0	0	0	0	458K	0	0	0
Total Non-Current Assets+	508K	928K	895K	630K	809K	476K	1.51M	26.34M	27.82M	19.07M
Property, Plant & Equipment	494K	905K	872K	607K	786K	453K	1.48M	1.54M	2.18M	1.54M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	5.53M	5.7M	0
Intangible Assets	0	0	0	0	0	0	0	19.15M	19.75M	17.36M
Long-Term Investments	0	0	0	0	0	0	0	99K	102K	0
Other Non-Current Assets	14K	23K	23K	23K	23K	23K	23K	-3.15M	78K	171K
Total Assets+	30.84M	22.5M	18.84M	30.14M	17.23M	8.41M	70.36M	71.86M	55.22M	35.35M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.61%	-0.27%	-0.16%	0.6%	-0.43%	-0.51%	7.37%	0.02%	-0.23%	-0.36%
Total Current Liabilities+	15.57M	19.76M	9.79M	3.38M	5.28M	2.97M	3.55M	7.06M	6.74M	7.58M
Accounts Payable	4.41M	1.99M	2.02M	1.03M	2.31M	886K	524K	915K	770K	859K
Days Payables Outstanding	22.37K	4.63K	3.01K	1.39K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	57K	63K	61K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	10.59M	14.82M	4.17M	99K	0	868K	0	4.47M	906K	1.8M
Current Ratio	1.95x	1.09x	1.83x	8.72x	3.11x	2.67x	19.37x	6.45x	4.07x	2.15x
Quick Ratio	1.95x	1.09x	1.83x	8.72x	3.11x	2.67x	19.37x	6.45x	4.07x	2.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	267K	492K	12.46M	302K	473K	186K	1.4M	10.24M	8.78M	8.7M
Long-Term Debt	0	0	0	0	0	0	0	221K	162K	92K
Capital Lease Obligations	0	0	0	0	473K	186K	1.4M	1.19M	1.44M	873K
Deferred Tax Liabilities	0	0	0	0	0	0	0	1.62M	0	762K
Other Non-Current Liabilities	267K	492K	402K	302K	0	0	0	7.21M	7.18M	6.97M
Total Liabilities	15.84M	20.25M	22.25M	3.69M	5.75M	3.15M	4.96M	17.3M	15.52M	16.29M
Total Debt+	0	0	0	0	722K	473K	1.53M	1.68M	2.15M	1.56M
Net Debt	-20.82M	-19.05M	-17.12M	-28.92M	-14.32M	-5.75M	-65.8M	-40.1M	-21.02M	-10.04M
Debt / Equity	-	-	-	-	0.06x	0.09x	0.02x	0.03x	0.05x	0.08x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	15M	2.25M	-3.41M	26.45M	11.49M	5.26M	65.41M	54.56M	39.7M	19.07M
Equity Growth %	0.57%	-0.85%	-2.52%	8.76%	-0.57%	-0.54%	11.44%	-0.17%	-0.27%	-0.52%
Book Value per Share	65.07	8.35	-9.60	42.45	6.99	2.77	5.37	89.00	61.61	14.14
Total Shareholders' Equity	16.05M	3.85M	-1.5M	29.36M	14.37M	8.03M	65.41M	54.56M	39.7M	19.07M
Common Stock	91K	117K	129K	15K	17K	29K	13K	16K	18K	3K
Retained Earnings	-144.78M	-172.03M	-194.17M	-219.46M	-235.54M	-248.09M	-271.28M	-290.97M	-309.32M	-334.97M
Treasury Stock	0	0	0	0	0	0	0	-288K	-288K	-288K
Accumulated OCI	0	0	-12.05M	0	0	0	0	-679K	32K	-1.18M
Minority Interest	-1.05M	-1.6M	-1.91M	-2.91M	-2.88M	-2.77M	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38.89M	-27.9M	-20.2M	-17.28M	-13.87M	-12.17M	-12.89M	-19.08M	-19M	-16.94M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.42%	0.28%	0.28%	0.14%	0.2%	0.12%	-0.06%	-0.48%	0%	0.11%
Net Income	-44.78M	-27.8M	-15.49M	-13.42M	-15.38M	-10.12M	-14.27M	-19.68M	-18.35M	-25.65M
Depreciation & Amortization	72K	157K	245K	272K	240K	201K	87K	85K	135K	137K
Stock-Based Compensation	3.2M	4.01M	3.41M	2.07M	340K	350K	416K	475K	552K	671K
Deferred Taxes	0	0	0	-4.08M	0	0	0	-1.43M	-1.64M	-888K
Other Non-Cash Items	8.16M	-11.41M	-10.74M	71K	72K	178K	166K	2.27M	-2M	8.07M
Working Capital Changes	-5.54M	7.15M	2.37M	-2.19M	855K	-2.78M	709K	-806K	2.31M	726K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	3.42M	-2.42M	27K	-987K	1.28M	-1.43M	-363K	-385K	-157K	123K
Cash from Investing+	-501K	-569K	-212K	-7K	0	-9K	-14K	-4.4M	-202K	-1K
Capital Expenditures	-501K	-569K	-212K	-7K	0	-9K	-14K	-116K	-202K	-1K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	-4.28K	0	0
Cash from Financing+	42.68M	26.71M	18.48M	29.09M	0	3.36M	74M	-1.93M	625K	5.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-3.32M	198K	166K	0	0	0	8.04M	-3M	-1.52M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-39.39M	-28.47M	-20.42M	-17.29M	-13.87M	-12.18M	-12.9M	-19.2M	-19.2M	-16.94M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.44%	0.28%	0.28%	0.15%	0.2%	0.12%	-0.06%	-0.49%	0%	0.12%
FCF per Share	-170.83	-105.68	-57.46	-27.74	-8.44	-6.41	-1.06	-31.31	-29.80	-12.56
FCF Conversion (FCF/Net Income)	0.89x	1.02x	1.33x	1.29x	0.91x	1.21x	0.90x	0.97x	1.04x	0.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-356.18%	-315.96%	-	-116.01%	-80.67%	-119.95%	-40.38%	-32.82%	-38.93%	-87.31%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-230.09%	-97.02%	-142.68%
Debt / Equity	-	-	-	-	0.06x	0.09x	0.02x	0.03x	0.05x	0.08x
FCF Conversion	0.89x	1.02x	1.33x	1.29x	0.91x	1.21x	0.90x	0.97x	1.04x	0.66x

Frequently Asked Questions

Growth & Financials

Theriva Biologics, Inc. (TOVX) grew revenue by 0.0% over the past year. Growth has been modest.

Theriva Biologics, Inc. (TOVX) reported a net loss of $26.2M for fiscal year 2024.

Dividend & Returns

Theriva Biologics, Inc. (TOVX) has a return on equity (ROE) of -87.3%. Negative ROE indicates the company is unprofitable.

Theriva Biologics, Inc. (TOVX) had negative free cash flow of $18.5M in fiscal year 2024, likely due to heavy capital investments.